Target Price | $408.00 |
Price | $340.16 |
Potential | 19.94% |
Number of Estimates | 38 |
38 Analysts have issued a price target Visa 2026 . The average Visa target price is $408.00. This is 19.94% higher than the current stock price. The highest price target is $446.25 31.19% , the lowest is $307.25 9.67% . | |
A rating was issued by 44 analysts: 35 Analysts recommend Visa to buy, 9 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Visa stock has an average upside potential 2026 of 19.94% . Most analysts recommend the Visa stock at Purchase. |
39 Analysts have issued a sales forecast Visa 2025 . The average Visa sales estimate is $40.7b . This is 4.58% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $42.1b 8.19% , the lowest is $38.8b 0.22% .
This results in the following potential growth metrics:
2024 | $35.9b | 10.02% |
---|---|---|
2025 | $40.7b | 13.22% |
2026 | $45.0b | 10.67% |
2027 | $49.5b | 9.97% |
2028 | $54.1b | 9.37% |
29 Analysts have issued an Visa EBITDA forecast 2025. The average Visa EBITDA estimate is $28.6b . This is 5.66% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $30.4b 12.41% , the lowest is $25.6b 5.46% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $25.1b | 9.71% |
---|---|---|
2025 | $28.6b | 13.88% |
2026 | $31.8b | 11.37% |
2027 | $35.1b | 10.44% |
2028 | $38.4b | 9.24% |
2029 | $42.5b | 10.77% |
2024 | 69.84% | 0.28% |
---|---|---|
2025 | 70.25% | 0.59% |
2026 | 70.69% | 0.63% |
2027 | 70.99% | 0.42% |
2028 | 70.91% | 0.11% |
40 Visa Analysts have issued a net profit forecast 2025. The average Visa net profit estimate is $22.5b . This is 12.29% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $23.4b 16.84% , the lowest is $21.4b 6.78% .
This results in the following potential growth metrics and future Net Margins:
2024 | $19.5b | 14.53% |
---|---|---|
2025 | $22.5b | 15.78% |
2026 | $25.3b | 12.23% |
2027 | $28.5b | 12.81% |
2028 | $32.6b | 14.46% |
2029 | $36.9b | 13.07% |
2024 | 54.16% | 4.09% |
---|---|---|
2025 | 55.38% | 2.26% |
2026 | 56.16% | 1.41% |
2027 | 57.61% | 2.58% |
2028 | 60.29% | 4.65% |
40 Analysts have issued a Visa forecast for earnings per share. The average Visa EPS is $11.67 . This is 13.85% higher than earnings per share in the financial year 2024. The highest EPS forecast is $12.14 18.44% , the lowest is $11.09 8.20% .
This results in the following potential growth metrics and future valuations:
2024 | $9.58 | 17.69% |
---|---|---|
2025 | $11.67 | 21.82% |
2026 | $13.09 | 12.17% |
2027 | $14.77 | 12.83% |
2028 | $16.90 | 14.42% |
2029 | $19.11 | 13.08% |
Current | 33.19 | 11.80% |
---|---|---|
2025 | 29.16 | 12.13% |
2026 | 25.98 | 10.91% |
2027 | 23.03 | 11.35% |
2028 | 20.12 | 12.64% |
2029 | 17.80 | 11.53% |
Based on analysts' sales estimates for 2025, the Visa stock is valued at an EV/Sales of 16.26 and an P/S ratio of 16.11 .
This results in the following potential growth metrics and future valuations:
Current | 17.00 | 8.42% |
---|---|---|
2025 | 16.26 | 4.36% |
2026 | 14.69 | 9.64% |
2027 | 13.36 | 9.07% |
2028 | 12.22 | 8.56% |
Current | 16.85 | 8.21% |
---|---|---|
2025 | 16.11 | 4.38% |
2026 | 14.56 | 9.64% |
2027 | 13.24 | 9.07% |
2028 | 12.11 | 8.56% |
Analyst | Rating | Action | Date |
---|---|---|---|
Macquarie |
Outperform
➜
Outperform
|
Unchanged | Jul 31 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jul 30 2025 |
UBS |
Buy
➜
Buy
|
Unchanged | Jul 30 2025 |
Truist Securities |
Buy
➜
Buy
|
Unchanged | Jul 17 2025 |
Deutsche Bank |
➜
Buy
|
Unchanged | Jul 17 2025 |
Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Jul 02 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Macquarie:
Outperform
➜
Outperform
|
Jul 31 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Jul 31 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jul 30 2025 |
Unchanged
UBS:
Buy
➜
Buy
|
Jul 30 2025 |
Unchanged
Truist Securities:
Buy
➜
Buy
|
Jul 17 2025 |
Unchanged
Deutsche Bank:
➜
Buy
|
Jul 17 2025 |
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Jul 02 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.